Beaming and droplet digital pcr analysis of mutant idh1 mrna in glioma patient serum and cerebrospinal fluid extracellular vesicles

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e109-

  Chen, Walter W ^a,b   Balaj, Leonora ^a,c   Liau, Linda M ^d   Samuels, Michael L ^e   Kotsopoulos, Steve K ^e   Maguire, Casey A ^a   LoGuidice, Lori ^f   Soto, Horacio ^d   Garrett, Matthew ^d   Zhu, Lin Dan ^a   Sivaraman, Sarada ^a   Chen, Clark ^g,h   Wong, Eric T ^g   Carter, Bob S ^h   Hochberg, Fred H ^a   Breakefield, Xandra O ^a,i   Skog, Johan ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c Amsterdam Gastroenterology Metabolism   (Netherlands)

^d UCLA MEDICAL CENTER   (United States)

^e RainDance Technologies   (United States)

^f Exosome Diagnostics Inc   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MA GenHosp   (United States)

Author keywords

BEAMing PCR; Biomarkers; Cancer; Droplet digital PCR; Extracellular vesicles

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; MESSENGER RNA; RNA;

ARTICLE; CELL VACUOLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; EXTRACELLULAR VESICLE; GLIOMA; HUMAN; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE; CANCER DIAGNOSIS; COPY NUMBER VARIATION; EXTRACELLULAR FLUID; MEMBRANE VESICLE;

EID: 84880339763     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.28     Document Type: Article

References (34)

1. Lecomte, T, Ceze, N, Dorval, E and Laurent-Puig, P (2010). Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol 34: 662-681.
2. Schwarzenbach, H, Hoon, DS and Pantel, K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11: 426-437.
3. Balaj, L, Lessard, R, Dai, L, Cho, YJ, Pomeroy, SL, Breakefield, XO et al. (2011). Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2: 180.
4. Skog, J, Würdinger, T, van Rijn, S, Meijer, DH, Gainche, L, Sena-Esteves, M et al. (2008). Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476.
5. Noerholm, M, Balaj, L, Limperg, T, Salehi, A, Zhu, LD, Hochberg, FH et al. (2012). RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 12: 22.
6. Hong, BS, Cho, JH, Kim, H, Choi, EJ, Rho, S, Kim, J et al. (2009). Colorectal cancer cellderived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 10: 556.
7. Di Vizio, D, Kim, J, Hager, MH, Morello, M, Yang, W, Lafargue, CJ et al. (2009). Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 69: 5601-5609.
8. Street, JM, Barran, PE, Mackay, CL, Weidt, S, Balmforth, C, Walsh, TS et al. (2012). Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 10: 5.
9. Weston, CL, Glantz, MJ and Connor, JR (2011). Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions. Fluids Barriers CNS 8: 14.
10. Thelwell, N, Millington, S, Solinas, A, Booth, J and Brown, T (2000). Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 28: 3752-3761.
11. Diehl, F, Li, M, He, Y, Kinzler, KW, Vogelstein, B and Dressman, D (2006). BEAMing: Singlemolecule PCR on microparticles in water-in-oil emulsions. Nat Methods 3: 551-559. (Pubitemid 43941774)
12. He, Y, Wu, J, Dressman, DC, Iacobuzio-Donahue, C, Markowitz, SD, Velculescu, VE et al. (2010). Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464: 610-614.
13. Li, M, Chen, WD, Papadopoulos, N, Goodman, SN, Bjerregaard, NC, Laurberg, S et al. (2009). Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 27: 858-863.
14. Diehl, F, Schmidt, K, Durkee, KH, Moore, KJ, Goodman, SN, Shuber, AP et al. (2008). Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135: 489-498.
15. Taly, V, Pekin, D, El Abed, A and Laurent-Puig, P (2012). Detecting biomarkers with microdroplet technology. Trends Mol Med 18: 405-416.
16. Pekin, D, Skhiri, Y, Baret, JC, Le Corre, D, Mazutis, L, Salem, CB et al. (2011). Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. Lab Chip 11: 2156-2166.
17. Zhong, Q, Bhattacharya, S, Kotsopoulos, S, Olson, J, Taly, V, Griffiths, AD et al. (2011). Multiplex digital PCR: Breaking the one target per color barrier of quantitative PCR. Lab Chip 11: 2167-2174.
18. Didelot, A, Kotsopoulos, SK, Lupo, A, Pekin, D, Li, X, Atochin, I et al. (2013). Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples. Clin Chem 59: 815-823.
19. Dang, L, White, DW, Gross, S, Bennett, BD, Bittinger, MA, Driggers, EM et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
20. Figueroa, ME, Abdel-Wahab, O, Lu, C, Ward, PS, Patel, J, Shih, A et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
21. Sjöblom, T, Jones, S, Wood, LD, Parsons, DW, Lin, J, Barber, TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274. (Pubitemid 44571966)
22. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
23. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
24. Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
25. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al.; Cancer Genome Atlas Research Network. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
26. Labussière, M, Idbaih, A, Wang, XW, Marie, Y, Boisselier, B, Falet, C et al. (2010). All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74: 1886-1890.
27. SongTao, Q, Lei, Y, Si, G, YanQing, D, HuiXia, H, XueLin, Z et al. (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103: 269-273.
28. Yen, KE, Bittinger, MA, Su, SM and Fantin, VR (2010). Cancer-associated IDH mutations: Biomarker and therapeutic opportunities. Oncogene 29: 6409-6417.
29. Capper, D, Simon, M, Langhans, CD, Okun, JG, Tonn, JC, Weller, M et al.; German Glioma Network. (2012). 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 131: 766-768.
30. Taniguchi, K, Uchida, J, Nishino, K, Kumagai, T, Okuyama, T, Okami, J et al. (2011). Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17: 7808-7815.
31. Higgins, MJ, Jelovac, D, Barnathan, E, Blair, B, Slater, S, Powers, P et al. (2012). Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 18: 3462-3469.
32. Chen, C, Skog, J, Hsu, CH, Lessard, RT, Balaj, L, Wurdinger, T et al. (2010). Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab Chip 10: 505-511.
33. Shao, H, Chung, J, Balaj, L, Charest, A, Bigner, DD, Carter, BS et al. (2012). Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 18: 1835-1840.
34. Shi, WM, Wildrick, DM and Sawaya, R (1998). Volumetric measurement of brain tumors from MR imaging. J Neurooncol 37: 87-93. (Pubitemid 28073580)